Searchable abstracts of presentations at key conferences on calcified tissues

ba0007lb4 | (1) | ICCBH2019

Impact of pubertal suppression on body composition and bone density in adolescents with gender dysphoria

Shepherd Sheila , Dewantoro Dixon , Ahmed Syed Faisal , Gerasimidis Kostas , Mason Avril , Shaikh Guftar , Wong SC , Kyriakou Andreas

Introduction: Pubertal suppression with gonadotrophin releasing hormone (GnRH) analogue is introduced after onset of puberty in adolescents with gender dysphoria (GD). As puberty is a critical period for bone accrual and changes in body composition, alterations in body composition and bone mass may be observed during treatment.Methods: Thirty-eight adolescents (32/38 assigned females at birth) with GD had dual energy X-ray absorptiometry (DXA) prior to s...

ba0004p44 | (1) | ICCBH2015

Closed image-guided vs open biopsies in children with bone lesions: a retrospective review of 112 biopsies performed on 104 patients

Papavasiliou Kyriakos , Bintoudi Antonia , Fontalis Andreas , Karanassos Marinos , Pellios Stavros , Tsitouridis Ioannis , Kirkos John

Introduction: Biopsy is a milestone in the diagnosis and treatment of skeletal lesions. Closed core-needle biopsy under computed tomography (CT) guidance is the gold standard. Open biopsy on the other hand may lead to more secure diagnosis.Objectives: Aim of this retrospective case-series study was the review of all biopsies (closed and open) performed at our department during the last eleven years in children suffering from bone tumours and the evaluati...

ba0003pp164 | Cell biology: osteoclasts and bone resorption | ECTS2014

Novel highly sensitive ELISA to measure free, bioactive, human soluble RANKL

Suciu Andreea , Breitwieser Andreas

RANKL, the receptor activator of nuclear factor kappa B ligand, is an essential factor for the formation of mature osteoclasts. Together with its receptor RANK and its antagonist Osteoprotegerin (OPG) RANKL is a key regulator in bone metabolism1. RANKL is a membrane-bound protein that can be segregated to a soluble form (sRANKL), whereas only the latter has been reported to be bioactive2. Due to its low circulating levels and the nature of the analyte bin...

ba0002p173 | (1) | ICCBH2013

Vitamin D prescription: a review of British National Formulary for children recommendations, and a proposal

Kouklinos Andreas , Lim Julian , Jacobs Benjamin

Aims: To review changes in the advice regarding vitamin D deficiency in the UK and compare these with other national guidance.Methods: All Vitamin D guidance in the Royal College of Paediatrics and Child Health 2003 guide (Medicines for Children) and in the eight editions since the British National Formulary for Children (BNFc) was first published in 2005 was reviewed.Results: Dosage and indications of prevalence are shown in the T...

ba0003pp304 | Osteoporosis: treatment | ECTS2014

Activin decoy receptor (IIA) ameliorates immobilisation induced loss of bone and muscle mass in mice

Lodberg Andreas , Thomsen Jesper Skovhus , Bruel Annemarie

Activin is a known physiologic regulator of bone metabolism. Ovariectomy-induced osteopenia has been shown to be attenuated by injection of the activin type IIA decoy receptor (ActRIIA-Fc). However, immobilization-induced osteopenia is driven by different pathways than ovariectomy-induced osteopenia, and the role of activin in immobilization-induced osteopenia has not yet been elucidated.The purpose of the study was to investigate the possible attenuatio...

ba0004p156 | (1) | ICCBH2015

Children with coeliac disease on gluten free diet have normal bone mass, geometry and muscle mass

Mackinder M , SC Wong , Tsiountsioura M , Shepherd S , Tellemer E , Kyriakou A , Buchanan E , Edwards C , SF Ahmed , P McGrogan , Gersimidis K

Objective: To evaluate musculoskeletal development using pQCT in children with coeliac disease (CD) on gluten free diet (GFD) compared with age and gender matched healthy controlsMethod: 38 children (18 males) with CD on GFD for a duration of 3.6 years (0.6, 12.5) underwent pQCT at 4%, 38 and 66% tibial sites. Bloods were collected in CD children only. Results reported as median (range).Result: Median TTG was 1.8 IU/l (0.1, 114) wi...

ba0001pp364 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Osteoporosis an independent predictor of mortality in hip fracture patients

Diamantopoulos Andreas P , Hoff Mari , Hochberg Marc , Haugeberg Glenn

Introduction: Mortality after hip fracture is increased. However, only a few studies have explored for predictors beyond gender and age. Thus our aim was to study risk factors associated with increased mortality in hip fracture patients.Methods: Hip fracture patients (>50 years) admitted to a county hospital in 2004–2005 were consecutively invited for assessment at the hospital osteoporosis centre. A broad spectre of data was collected. Standard...

ba0002p171 | (1) | ICCBH2013

Vitamin D levels and signs of metabolic bone disease in adolescents with idiopathic scoliosis

Adodra Annika , Kouklinos Andreas , Julies Priscilla , Shaw Mathew , Jacobs Benjamin

Objective: Biochemical assessment of teenage patients with adolescent idiopathic scoliosis (AIS).Methods: Blood sampling from 120 patients with AIS aged 12–17 years. The patients all had significant scoliosis and blood samples were taken a few days or weeks before they underwent scoliosis surgery. Serum 25-hydroxy-vitamin D (25-OHD), calcium, phosphate, alkaline phosphatase and parathyroid hormone (PTH) were measured. Patients with a 25-OHD level be...

ba0003pp37 | Bone biomechanics and quality | ECTS2014

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Roschger Andreas , Roschger Paul , Kneissel Michaela , Rauch Frank

Children with osteogenesis imperfecta (OI) still suffer from frequent fractures, despite bisphosphonate treatment. Thus new therapeutic approaches are needed. Sclerostin is a protein that is thought to inhibit bone formation. Treatment with sclerostin antibodies (SclAB) increases bone mass in animal models and in clinical trials and may be a rational therapy for OI as well.Transgenic (TgOI) Col1a1Jrt/+ mice were gene...